alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 176–200 of 642 studies published 2011 (page 8 of 26) · 27,380 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Nature reviews. Neuroscience 2011-11-03

This article examines mechanisms of blood-brain barrier dysfunction in neurodegenerative disorders, notably Alzheimer's disease, and highlights therapeutic opportunities relating to these neurovascular deficits.

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Adherence to a Mediterranean diet and plasma fatty acids: data from the Bordeaux sample of the Three-City study

✓ Peer-reviewed alzhub usefulness score 57 out of 100. The British journal of nutrition 2011-02-08

Higher adherence to a Mediterranean diet (MeDi) and n-3 PUFA may both contribute to decreased dementia risk, but the association between MeDi adherence and lipid status is unclear. 4 key findings →

Design: cross-sectional Participants: 1,050 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Stress and inflammation reduce brain-derived neurotrophic factor expression in first-episode psychosis: a pathway to smaller hippocampal volume

✓ Peer-reviewed alzhub usefulness score 57 out of 100. The Journal of clinical psychiatry 2011-05-18

Biological changes activated by stress represent a significant factor influencing brain structure and function in first-episode psychosis through an effect on BDNF. 4 key findings →

Design: case-control study Participants: 19 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Stroke 2011-07-21

This statement serves as an overall guide for practitioners to gain a better understanding of VCI and dementia, prevention, and treatment. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Mild cognitive impairment and dementia: the importance of modifiable risk factors

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Deutsches Arzteblatt international 2011-11-04

Modifiable risk factors for MCI should be sought (at the very latest) in persons who already have MCI, as their optimal treatment may improve these patients' cognitive performance or keep the existing deficits from progressing. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The diagnostic challenge of psychiatric symptoms in neurodegenerative disease: rates of and risk factors for prior psychiatric diagnosis in patients with early neurodegenerative disease

✓ Peer-reviewed alzhub usefulness score 56 out of 100. The Journal of clinical psychiatry 2011-02-01

Depression was the most common psychiatric diagnosis in all groups. 2 key findings →

Participants: 69 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Archives of neurology 2011-05-09

The INNOTEST and INNO-BIA CSF platforms perform equally well in identifying individuals with underlying amyloid plaque pathology. 2 key findings →

Participants: 103 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Neuron 2011-10-01

Inclusions composed of α-synuclein (α-syn), i.e., Lewy bodies (LBs) and Lewy neurites (LNs), define synucleinopathies including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Incidence of dementia and cognitive impairment, not dementia in the United States

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Annals of neurology 2011-03-18

The incidence of CIND is greater than the incidence of dementia, and those with CIND are at high risk of progressing to dementia, making CIND a potentially valuable target for treatments aimed at slowing cognitive decline. 1 key finding →

Participants: 456 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The Montreal Cognitive Assessment and the mini-mental state examination as screening instruments for cognitive impairment: item analyses and threshold scores

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Dementia and geriatric cognitive disorders 2011-01-29

135 subjects enrolled in a longitudinal clinicopathologic study were administered the MoCA by a single physician and the MMSE by a trained research assistant. 4 key findings →

Design: longitudinal study Participants: 135 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Plasma sphingomyelins are associated with cognitive progression in Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Journal of Alzheimer's disease : JAD 2011-01-01

Plasma sphingolipids have been shown to predict cognitive impairment and hippocampal volume loss, but there is little research in patients with Alzheimer's disease (AD). 4 key findings →

Design: cross-sectional Participants: 120 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Cognitive decline in patients with dementia as a function of depression

✓ Peer-reviewed alzhub usefulness score 56 out of 100. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 2011-04-01

There is evidence that major depression increases the risk for dementia, but there is conflicting evidence as to whether depression may accelerate cognitive decline in dementia. 4 key findings →

Design: cohort study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Health and nutrition promotion program for patients with dementia (NutriAlz): cluster randomized trial

✓ Peer-reviewed alzhub usefulness score 55 out of 100. The journal of nutrition, health & aging 2011-12-01

The NutriAlz program had no effect on functional decline in Alzheimer disease patients living at home over one year, but reduced the risk for malnutrition, as recommendations concerning diet and exercise were provided. 2 key findings →

Participants: 448 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Amygdala atrophy is prominent in early Alzheimer's disease and relates to symptom severity

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Psychiatry research 2011-09-14

Despite numerous studies on the role of medial temporal lobe structures in Alzheimer's disease (AD), the magnitude and clinical significance of amygdala atrophy have been relatively sparsely investigated. 4 key findings →

Participants: 90 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed